Exploring how double-stranded RNA affects breast cancer treatment
Targeting cellular double-stranded RNA homeostasis in breast cancer
This study is looking at how a special type of RNA can help the immune system fight breast cancer better, especially when a protein called DDX3X is blocked, and it aims to find new ways to improve treatments for breast cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10866525 on NIH RePORTER |
What this research studies
This research investigates the role of double-stranded RNA (dsRNA) in breast cancer, particularly how its accumulation can influence immune responses against tumors. The study focuses on a protein called DDX3X, which, when inhibited, leads to increased levels of dsRNA in breast cancer cells. This accumulation is believed to enhance the immune system's ability to recognize and attack tumors by boosting the presentation of tumor antigens. By understanding these mechanisms, the research aims to develop new strategies for improving immunotherapy outcomes for breast cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer who may benefit from enhanced immunotherapy approaches.
Not a fit: Patients with non-breast cancer conditions or those whose tumors are already responsive to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for breast cancer patients.
How similar studies have performed: Other research has shown promising results in utilizing dsRNA to enhance immune responses in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Han, Cecil — Georgetown University
- Study coordinator: Han, Cecil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.